Surgical Oncology Program »  Meet the Team »  Medical Oncology »  Emily Bergsland, M.D.

Emily Bergsland, M.D.

Professor of Clinical Medicine
Division of Hematology Oncology
Department of Medicine
Ernest Rosenbaum, MD Endowed Chair of Medical Oncology

Contact Information

1825 Fourth St., Fourth Floor
San Francisco, CA 94158
Phone: (415) 353-9888
Fax: (415) 353-9931


Open Popup
  • UniversUniversity of Wisconsin, B.S., 1985, Biochemistry and Molecular Biology
  • University of Minnesota, M.D., 1982
  • 1989-92, Intern, Dept. of Medicine, University of California San Francisco
  • 1990-92, Resident, Dept. of Medicine, University of California San Francisco
  • 1992-92, Chief Resident and Assistant Chief of the Medical Service, Dept. of Medicine, University of California San Francisco
  • 1993-92, Fellow, Medical Oncology, University of California San Francisco
  • 1994-1992, Research Fellow (P I: Douglas Hanahan, Ph.D.), Department of Biochemistry and Biophysics, University of California San Francisco
  • American Board of Internal Medicine
  • American Board of Internal Medicine: Medical Oncology - Subspecialty
  • Angiogenesis Inhibitors
  • Colorectal Neoplasms
  • Neuroendocrine Tumors
  • Pancreatic Neoplasms
  • Vascular Endothelial Growth Factor

Dr. Emily Bergsland is currently a Professor of Clinical Medicine and holds the Ernest Rosenbaum, MD Endowed Chair of Medical Oncology. She received her medical degree from the University of Minnesota and completed an internship, residency, and chief residency in internal medicine at UCSF. She subsequently completed a fellowship in Medical Oncology and was a Molecular Medicine fellow before joining the UCSF faculty in 1998.

Dr. Bergsland has led numerous clinical studies in patients with gastrointestinal malignancies. Her current efforts are focused on clinical and translational research related to neuroendocrine tumors. At a national level, Dr. Bergsland is a member of the Neuroendocrine Tumor Task force for the National Cancer Institute and a member of the NCCN NET guidelines panel. She is also the study chair for a national study of a novel treatment for patients with carcinoid tumors performed by the ALLIANCE for Clinical Trials and funded by the National Cancer Institute.

Bergsland And Nakakura

Most recent publications from a total of 73
  1. Fidelman N, Kerlan RK, Hawkins RA, Pampaloni M, Taylor AG, Kohi MP, Kolli KP, Atreya CE, Bergsland EK, Kelley RK, Ko AH, Korn WM, Van Loon K, McWhirter RM, Luan J, Johanson C, Venook AP. Radioembolization with 90Y glass microspheres for the treatment of unresectable metastatic liver disease from chemotherapy-refractory gastrointestinal cancers: final report of a prospective pilot study. J Gastrointest Oncol. 2016 Dec; 7(6):860-874. View in PubMed
  2. Kunz PL, Balise RR, Fehrenbacher L, Pan M, Venook AP, Fisher GA, Tempero MA, Ko AH, Korn WM, Hwang J, Bergsland EK. Oxaliplatin-Fluoropyrimidine Chemotherapy Plus Bevacizumab in Advanced Neuroendocrine Tumors: An Analysis of 2 Phase II Trials. Pancreas. 2016 Nov; 45(10):1394-1400. View in PubMed
  3. Kulke MH, Hörsch D, Caplin ME, Anthony LB, Bergsland E, Öberg K, Welin S, Warner RR, Lombard-Bohas C, Kunz PL, Grande E, Valle JW, Fleming D, Lapuerta P, Banks P, Jackson S, Zambrowicz B, Sands AT, Pavel M. Telotristat Ethyl, a Tryptophan Hydroxylase Inhibitor for the Treatment of Carcinoid Syndrome. J Clin Oncol. 2017 Jan; 35(1):14-23. View in PubMed
  4. Strosberg JR, Cives M, Hwang J, Weber T, Nickerson M, Atreya CE, Venook A, Kelley RK, Valone T, Morse B, Coppola D, Bergsland EK. A phase II study of axitinib in advanced neuroendocrine tumors. Endocr Relat Cancer. 2016 May; 23(5):411-8. View in PubMed
  5. Chow OS, Kuk D, Keskin M, Smith JJ, Camacho N, Pelossof R, Chen CT, Chen Z, Avila K, Weiser MR, Berger MF, Patil S, Bergsland E, Garcia-Aguilar J. KRAS and Combined KRAS/TP53 Mutations in Locally Advanced Rectal Cancer are Independently Associated with Decreased Response to Neoadjuvant Therapy. Ann Surg Oncol. 2016 Aug; 23(8):2548-55. View in PubMed
  6. Mulvey CK, Bergsland EK. Systemic Therapies for Advanced Gastrointestinal Carcinoid Tumors. Hematol Oncol Clin North Am. 2016 Feb; 30(1):63-82. View in PubMed
  7. Munster P, Aggarwal R, Hong D, Schellens JH, van der Noll R, Specht J, Witteveen PO, Werner TL, Dees EC, Bergsland E, Agarwal N, Kleha JF, Durante M, Adams L, Smith DA, Lampkin TA, Morris SR, Kurzrock R. First-in-Human Phase I Study of GSK2126458, an Oral Pan-Class I Phosphatidylinositol-3-Kinase Inhibitor, in Patients with Advanced Solid Tumor Malignancies. Clin Cancer Res. 2016 Apr 15; 22(8):1932-9. View in PubMed
  8. Hope TA, Verdin EF, Bergsland EK, Ohliger MA, Corvera CU, Nakakura EK. Correcting for respiratory motion in liver PET/MRI: preliminary evaluation of the utility of bellows and navigated hepatobiliary phase imaging. EJNMMI Phys. 2015 Dec; 2(1):21. View in PubMed
  9. Hope TA, Pampaloni MH, Nakakura E, VanBrocklin H, Slater J, Jivan S, Aparici CM, Yee J, Bergsland E. Simultaneous (68)Ga-DOTA-TOC PET/MRI with gadoxetate disodium in patients with neuroendocrine tumor. Abdom Imaging. 2015 Aug; 40(6):1432-40. View in PubMed
  10. Bendell JC, Kelley RK, Shih KC, Grabowsky JA, Bergsland E, Jones S, Martin T, Infante JR, Mischel PS, Matsutani T, Xu S, Wong L, Liu Y, Wu X, Mortensen DS, Chopra R, Hege K, Munster PN. A phase I dose-escalation study to assess safety, tolerability, pharmacokinetics, and preliminary efficacy of the dual mTORC1/mTORC2 kinase inhibitor CC-223 in patients with advanced solid tumors or multiple myeloma. Cancer. 2015 Oct 1; 121(19):3481-90. View in PubMed
  11. View All Publications
Publications provided by UCSF Profiles, powered by CTSI at UCSF. View profile of Emily Bergsland, M.D.
Please note: UCSF Profiles publications are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact CTSI for help.

X